

## **Study Published in *Stroke* Shows Drug Effective**

*Active ingredient of Remedy Pharmaceutical's drug, RP-1127, offers promise to ischemic stroke victims*

New York, NY, USA - September 23, 2007 – Remedy Pharmaceuticals, Inc. today announced that an important human study validating the use of the key ingredient in RP-1127 for treating stroke was published in the prestigious journal, *Stroke*.

The publication titled “Sulfonylureas Improve Outcome in Patients With Type 2 Diabetes and Acute Ischemic Stroke” concluded that diabetic patients with acute ischemic stroke treated with the active ingredient of RP-1127 and other drugs in its class had better outcomes even after adjusting for the known predictors of poor outcome.

“This data provides further evidence that sulfonylureas may be beneficial in patients with acute ischemic stroke,” said Sven Jacobson, Chief Executive Officer of Remedy Pharmaceuticals

Stroke is the third leading cause of death in America, surpassed only by heart disease and cancer, and is the primary cause of serious long-term disability in adults. There are 795,000 strokes in the U.S. each year, resulting in nearly 150,000 deaths. Annual costs to the healthcare system are estimated at \$56.8 billion.

Details of the publication follow:

Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, Weih M, Dirnagl U. *Stroke*. 2007 Sep;38(9):2526-30.

### **About RP-1127**

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of  $NC_{Ca-ATP}$  channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

### **About Remedy Pharmaceuticals**

Remedy Pharmaceuticals, Inc. is a development stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: [info@remedypharmaceuticals.com](mailto:info@remedypharmaceuticals.com)